Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is a promising biotech company with a focus on precision medicine for oncology patients. The company's strong pipeline of clinical-stage product candidates shows potential for targeted therapies in multiple patient populations. Their positive clinical trial data and potential for off-label use in HLA-A*02:01-positive mUM, along with a planned NDA submission and potential US launch in 2027, make them a strong investment opportunity. Additionally, the company's strong safety and tolerability profile, as well as its potential for significant revenue growth, further support a positive outlook for the stock.

Bears say

IDEAYA Biosciences is facing potential key risks including disappointing PFS readouts for darovasertib, challenged market opportunities in neo-adjuvant UM, and uncertainty around commercialization for pipeline programs. Additionally, despite the excitement from KOLs and potential for treating past progression, the company's estimated average treatment duration of 7 months may be conservative, limiting potential revenue. Therefore, the analyst has a negative outlook on the company's stock.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.